Technology-driven gene therapy CDMO from oligonucleotide to xRNA
Location: South Korea, Seoul
Employees: 51-200
Founded date: 1983
Investors 2
| Date | Name | Website |
| 18.05.2023 | Synergy IB... | synergyib.... |
| - | E&Inve... | eninvestme... |
Mentions in press and media 4
| Date | Title | Description | Source |
| 21.11.2023 | ST Pharm Presented '100-Day Expedite Strategy', Preparedness... | SEOUL, South Korea, Nov. 21, 2023 /PRNewswire/ -- Nov. 21, 2023 local time, ST Pharm announced 'Rapi... | en.prnasia... |
| 19.09.2023 | ST Pharm breaks ground on 2nd State-of-the-Art Oligonucleoti... | SEOUL, South Korea, Sept. 19, 2023 /PRNewswire/ -- ST Pharm successfully marked the completion of it... | en.prnasia... |
| 03.08.2022 | ST Pharm Presents Phase 1 Clinical Trial Results of HIV Trea... | - STP0404 is the only clinical safety proven HIV treatment candidate with a novel mechanism that can... | en.prnasia... |
| 29.11.2021 | ST Pharm announces expansion of oligonucleotide facility, ta... | SEOUL, South Korea, Nov. 29, 2021 /PRNewswire/ -- On November 24, ST Pharm Co. Ltd., an API CDMO com... | en.prnasia... |